Aducanumab: European agency rejects Alzheimer's drug over efficacy and safety concerns. Mahase E. BMJ 2021;375:n3127.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Mahase E. Aducanumab: European agency rejects Alzheimer's drug over efficacy and safety concerns. BMJ 2021;375:n3127.
PMID: 34930757